VAN WIJMEERSCH, Bart

Email Alert RSS Feed

Profile

Full Name
VAN WIJMEERSCH, Bart
Email
bart.vanwijmeersch@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Results 81-100 of 126 (Search time: 0.004 seconds).

show all
Issue DateTitleContributor(s)TypeCat.
812018Twelve Weeks of Medium-Intensity Exercise Therapy Affects the Lipoprotein Profile of Multiple Sclerosis Patients.JORISSEN, Winde; VANMIERLO, Tim; WENS, Inez; SOMERS, Veerle; VAN WIJMEERSCH, Bart; BOGIE, Jeroen; Remaley, Alan; OP 'T EIJNDE, Bert; HENDRIKS, JeromeJournal ContributionA1
822018Lack of apparent association between lymphocyte repopulation kinetics and autoimmune events in alemtuzumab-treated patients with relapsing-remitting Multiple Sclerosis through 6 years: CARE-MS extensionWiendl, H.; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; JACOBS, Andre; VAN WIJMEERSCH, BartJournal ContributionM
832018Treatment Experiences of Patients with MS: Results From the Global vs MS (TM) SurveyBass, Ann; VAN WIJMEERSCH, Bart; Boster, Aaron; Mayer, Lori; Mandel, Matt; Sharrock, Kersten; Mitchell, Colin P.; Singer, BarryJournal ContributionM
842018No correlation between lymphocyte pharmacodynamics and autoimmune adverse events following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosisWiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; Jacobs, Alessia; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, BartJournal ContributionM
852018Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study)VAN WIJMEERSCH, Bart; Vermersch, P.; Boyko, A.; de Seze, J.; Hartung, H. -P.; Havrdova, E. Kubala; Inshasi, J. Said; McCombe, P.; Montalban, X.; Pozzili, C.; Melanson, M.; Daizadeh, N.; Rodriguez, C.; Selmaj, K.Journal ContributionM
862018Durable suppression of MRI disease activity and slowing of brain volume loss in alemtuzumab-treated patients with active RRMS: 7-year follow-up of CARE-MS I (TOPAZ Study)Schippling, S.; Arnold, D.; Barnett, M.; Comi, G.; Laganke, C.; Rovira, A.; Traboulsee, A.; Melanson, M.; Daizadeh, N.; Nakamura, K.; VAN WIJMEERSCH, Bart; Pelletier, D.Journal ContributionM
872018Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I)Broadley, S.; Wiendl, Heinz; Fernandez, O.; Freedman, M. S.; Izquierdo, G.; Lycke, J.; Pozzilli, C.; Sharrack, B.; Singer, B. A.; Steingo, B.; Vermersch, P.; Wray, S.; VAN WIJMEERSCH, Bart; Ziemssen, T.; Margolin, D. H.; Thangavelu, K.; Boster, A.Journal ContributionM
882018Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study)Vermersch, Patrick; Coles, Alasdair J.; Boyko, Alexey N.; De Seze, Jerome; Hartung, Hans-Peter; Havrdova, Eva; Inshasi, Jihad Said; McCombe, Pamela; Montalban, Xavier; Pozzilli, Carlo; Selmaj, Krzysztof W.; Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; VAN WIJMEERSCH, BartJournal ContributionM
892018Improving fatigue in multiple sclerosis by smartphone-supported energy management: The MS TeleCoach feasibility studyD'hooghe, Marie; Van Gassen, Geert; Kos, Daphne; Bouquiaux, Olivier; Cambron, Melissa; Decoo, Danny; Lysandropoulos, Andreas; VAN WIJMEERSCH, Bart; Willekens, Barbara; Penner, Iris-Katharina; Nagels, GuyJournal ContributionA1
902018Determinants of MS re-activation after discontinuing therapiesHusin, H.; Wallace, J.; Malpas, C.; Sharmin, S; Horakova, D.; Havrdova, E. Kubala; Izquierdo, G.; Eichau, S.; Prat, A.; Girard, M.; Duquette, P.; Trojano, M.; Grammond, P.; Lugaresi, A.; Onofrj, M.; Ozakbas, S.; Butzkueven, H.; Sola, P.; Ferraro, D.; Alroughani, R.; Grand'Maison, F.; Terzi, M.; Lechner-Scott, J.; Boz, C.; Hupperts, R.; Shaygannejad, V.; Bergamaschi, R.; Pucci, E.; Van Pesch, V.; Hodgkinson, S.; McCombe, P.; Granella, F.; Slee, M.; VAN WIJMEERSCH, Bart; Karabudak, R.; Prevost, J.; Petersen, T.; Spitaleri, D.; Barnett, M.; Solaro, C.; Iuliano, G.; Verheul, F.; Ramo-Tello, C.; Turkoglu, R.; Fernandez Bolanos, R.; Butler, E.; Macdonell, R.; Soysal, A.; Betancur, M. Moreno; Kalincik, T.Journal ContributionM
912018No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosisWiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, BartJournal ContributionM
922018A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosisLaureys, Guy; Willekens, Barbara; Vanopdenbosch, Ludo; Deryck, Olivier; Selleslag, Dominik; D'Haeseleer, Miguel; De Becker, Ann; Dubois, Benedicte; Dierickx, Daan; Perrotta, Gaetano; De Wilde, Virginie; van Pesch, Vincent; Straetmans, Nicole; Dive, Dominique; Beguin, Yves; VAN WIJMEERSCH, Bart; Theunissen, Koen; Kerre, Tessa; Van de Velde, AnnJournal ContributionA1
932017Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analysesComi, G.; Boster, A.; Alroughani, R.; Berkovich, R.; Izquierdo, G.; Kantor, D.; Laganke, C.; Limmroth, V.; Macdonell, R.; Moreau, T.; Sharrack, B.; Wiendl, H.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Melanson, M.; Freedman, M. S.Journal ContributionM
942017Cytotoxic CD4+T Cells Drive Multiple Sclerosis ProgressionPEETERS, Liesbet; VANHEUSDEN, Marjan; SOMERS, Veerle; VAN WIJMEERSCH, Bart; STINISSEN, Piet; BROUX, Bieke; HELLINGS, NielsJournal ContributionA1
952017Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study.Costers, Lars; Gielen, Jeroen; Eelen, Piet L.; Van Schependom, Jeroen; Laton, Jorne; Van Remoortel, Ann; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Seeldrayers, Pierrette; Haelewyck, Marie-Claire; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Langdon, Dawn; Nagels, GuyJournal ContributionM
162017Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammationVANHEUSDEN, Marjan; BROUX, Bieke; Welten, Suzanne P. M.; PEETERS, Liesbet; Panagioti, Eleni; VAN WIJMEERSCH, Bart; SOMERS, Veerle; STINISSEN, Piet; Arens, Ramon; HELLINGS, NielsJournal ContributionA1
172016B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responsesFRAUSSEN, Judith; CLAES, Nele; VAN WIJMEERSCH, Bart; VAN HORSSEN, Jack; STINISSEN, Piet; Hupperts, Raymond; SOMERS, VeerleJournal ContributionA1
182016Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).Coles, A. J.; Boyko, A. N.; Cohen, J. A.; De Seze, J.; Fox, E. J.; Havrdova, E.; Hartung, H. -P.; Inshasi, J. S.; McCombe, P.; Selmaj, K. W.; Vermersch, P.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Montalban, X.Journal ContributionM
192016Brain atrophy by automated MRI reading in long-term natalizumab treated patients: Real world data suggests brain atrophy rates in range of healthy individualsHorakova, Dana; Uher, T.; Vaneckova, M.; Krasensky, J.; Seidl, Z.; van Pesch, V.; Lysandropoulos, A.; VAN WIJMEERSCH, Bart; Ribbens, A.; van Hecke, W.; Dong, Q.; Farkas, M.; Hyde, R.; Koendgen, H.Journal ContributionM
202016Effects of an individual 12 weeks community located running program on physical capacity, walking, cognitive function, dual tasking and brain volumes and structures in persons with Multiple Sclerosis.FEYS, Peter; MOUMDJIAN, Lousin; Vanhalewyck, F.; WENS, Inez; OP 'T EIJNDE, Bert; VAN WIJMEERSCH, Bart; POPESCU, Veronica; Dufour, A.; Delva, S.; VAN ASCH, PaulJournal ContributionM
show all